title: Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new?
abstract: OBJECTIVE
  To provide a context to understand the opportunity for novel therapeutic modalities to transform the treatment of hereditary angioedema (HAE).
  
  
  METHODS
  MEDLINE and PubMed were searched to identify studies involving current treatment of HAE in the United States.
  
  
  METHODS
  Studies were selected based on their relevance to the treatment of HAE.
  
  
  RESULTS
  The current HAE treatment strategy is far from satisfactory, and its limitations create an unmet clinical need. Current prophylactic treatment exposes patients with HAE to significant risk of adverse effects, and the efficacy of prophylactic treatment, although generally good, is far from perfect.
  
  
  CONCLUSIONS
  No specific treatment is currently available in the United States for acute HAE attacks that will reliably work, resulting in a significant unmet clinical need. The emergence of several promising drugs for the treatment of HAE attacks is, thus, an extraordinarily important development in the management of these patients.
authors.affiliation: Veterans Affairs Medical Center, San Diego, California, USA. bzuraw@ucsd.edu
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Zuraw
mesh_terms: D015119:Aminocaproic Acid / Q000627:therapeutic use; D045930:Anabolic Agents / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D054179:Angioedemas, Hereditary / Q000175:diagnosis / Q000628:therapy*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors; D010455:Peptides / Q000627:therapeutic use
chemical_list: D045930:Anabolic Agents; D000728:Androgens; D000933:Antifibrinolytic Agents; D050718:Complement C1 Inhibitor Protein; D004965:Estrogen Antagonists; D010455:Peptides; D007610:Kallikreins; D003613:Danazol; D015119:Aminocaproic Acid